Results of Prospective Randomized, Open Label, Non -Inferiority Study of Tbo-Filgrastim (Granix®) Versus Filgrastim (Neupogen®) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non -Hodgkin Lymphoma. Bhamidipati PK et al. Biol Blood Marrow Transplant. 2017 Aug 7. pii: S1083-8791(17)30619-5. doi: 10.1016/j.bbmt.2017.07.023. [Epub ahead of print]. Multiple myeloma with extramedullary disease: impact of autologous stem…
Uterine Extramedullary Plasmacytoma as a Primary Manifestation of Multiple Myeloma. Codorniz A et al. Rev Bras Ginecol Obstet. 2017 Aug 23. doi: 10.1055/s-0037-1605373. [Epub ahead of print]. Autoimmune HIT due to apheresis catheter heparin flushes for stem-cell harvesting before autotransplantation for myeloma. Mian H et al. Blood. 2017 Aug 22. pii: blood-2017-06-788679. doi: 10.1182/blood-2017-06-788679. [Epub ahead of print]. Infectious complications in multiple myeloma receiving autologous…
The Danish biotechnology company, Genmab, have announced that the Phase III trial, ALCYONE, has achieved its primary endpoint of improving progression-free survival in newly diagnosed myeloma patients. This study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone. Treatment including daratumumab was demonstrated to reduce the risk of disease…
The Scottish Medicines Consortium (SMC) has approved the use of carfilzomib (Kyprolis®) in combination with dexamethasone for myeloma patients who have received at least one previous treatment. The approval is based on results from the ENDEAVOR trial which showed that progression-free survival was significantly improved in patients treated with carfilzomib in combination with dexamethasone compared…
This NICE guidance outlines recommendations for children and adults with suspected cancer, including primary care investigations and referral recommendations to secondary care.
Meta-analysis of results from three randomised control trials has demonstrated that maintenance treatment with lenalidomide (Revlimid®) following high-dose therapy and autologous stem cell transplantation (HDT-ASCT) in newly diagnosed myeloma patients has a significant overall survival (OS) benefit. Published in the Journal of Clinical Oncology, the results of this meta-analysis, which used data pooled from the…
These updated guidelines, produced by the British Society of Haematology and Myeloma UK summarise a national consensus for the use of imaging in the diagnosis and management of myeloma patients.
A study, published recently in Clinical Lymphoma, Myeloma and Leukemia, has further validated the use of the SKY92 gene expression signature as a potentially valuable prognostic tool to evaluate myeloma patients. Compared with seven other gene expression profiling classifiers including UAMS 70, UAMS 80 and IFM15, the researchers found that SKY92 identified the largest proportion (21%)…
The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies. Sakellari I et al. Clin Lymphoma Myeloma Leuk. 2017 Jun 29. pii: S2152-2650(17)30096-4. doi: 10.1016/j.clml.2017.06.008. [Epub ahead of print]. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Multiple Myeloma. Ghosh N et al. Biol Blood Marrow…
Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods. Ramsenthaler C et al. Qual Life Res. 2017 Jul 27. doi: 10.1007/s11136-017-1660-z. [Epub ahead of print]. The Experience of Myeloma Caregivers During Home-Based Oral Chemotherapy Treatment: A Qualitative Study. Morris M et al. Semin Oncol Nurs. 2017 Jul 24. pii: S0749-2081(17)30045-1. doi: 10.1016/j.soncn.2017.05.010. [Epub ahead…